Recent

% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • bioimmunomabman bioimmunomabman May 6, 2013 1:37 PM Flag

    New Amgen-IMGN compounds in phase I

    I learned from the recent AVEO, Tivo FDA debacle, there are several approved drugs for RCC that work OK, but only for a limited time and with harsh side effects. There's room for improvement in efficacy and safety with blockbuster potential in this indication. The ONXX drug sells over $1BB and is not all that efficacous, so there's room for improvement and large profits.

    I doubt anything works for Glioma, so the hurdle should be low, maybe AMGN can get on a very fast track/breakthrough.

    AMG 595 - This TAP compound, in development by Amgen, is in Phase I clinical testing for recurrent malignant glioma.
    AMG 172 - This TAP compound, in development by Amgen, is in Phase I clinical testing for clear cell renal cell carcinoma (ccRCC).

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
IMGN
13.14-0.32(-2.38%)3:03 PMEDT